Почетна › Akutna mijeloidna leukemija › Kalifornija › Orange
Kliničke studije za Akutna mijeloidna leukemija u gradu Orange, CA
12 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u gradu Orange i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Тражи се учесникФаза 2
- UCI Health Chao Family Comprehensive Cancer Center, Orange
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Тражи се учесникФаза 3
- University of California, Irvine, Orange
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Тражи се учесникФаза 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Тражи се учесникФаза 2/3
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Тражи се учесникФаза 3
- Children's Hospital of Orange County, Orange
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Тражи се учесникФаза 1/2
- Children's Hospital of Orange County, Orange
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Тражи се учесникФаза 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Тражи се учесникФаза 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Тражи се учесникФаза 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Тражи се учесникФаза 4
- UCI Irvine Health, Orange
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Тражи се учесникОпсервациона студија
- Children's Hospital of Orange County (CHOC), Orange
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Тражи се учесникФаза 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
Studije za Akutna mijeloidna leukemija u drugim gradovima
- Houston, TX88 студија
- New York City, NY51 студија
- Boston, MA44 студија
- Baldwin Park, CA41 студија
- Seattle, WA40 студија
- Durham, NC34 студија
- Columbus, OH34 студија
- Philadelphia, PA33 студија
- Atlanta, GA30 студија
- Tampa, FL30 студија
- Chicago, IL27 студија
- Los Angeles, CA25 студија
Ostale studije u gradu Orange
- Немалоклетни карцином плућа28 студија
- Метастатски карцином21 студија
- Рак јајника16 студија
- Колоректални карцином16 студија
- Рак (све врсте)15 студија
- Рак панкреаса15 студија
- Рак плућа15 студија
- Рак јетре (хепатоцелуларни карцином)14 студија
- Меланом14 студија
- Мажорна депресивна поремећеност13 студија
- Рак желуца13 студија
- Рак простате13 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.